9,564 results match your criteria Ovarian Cancer* Obstetrics and Gynecology


Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.

Psychoneuroendocrinology 2019 Apr 6;106:244-251. Epub 2019 Apr 6.

Diabetes Research Institute, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Miller School of Medicine, University of Miami, United States.

Background: Prior research demonstrates a protective role for oxytocin in ovarian cancer based on its anti-proliferative, anti-migratory, and anti-invasive effects in vitro and in vivo. However, the role of endogenous oxytocin has not been examined in ovarian cancer patients. Oxytocin also has anti-inflammatory properties that have not been examined in cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.psyneuen.2019.04.007DOI Listing
April 2019
1 Read

Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts.

Sci Rep 2019 Apr 19;9(1):6314. Epub 2019 Apr 19.

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.

As patient derived xenograft (PDX) models are increasingly used for preclinical drug development, strategies to account for the nonhuman component of PDX RNA expression data are critical to its interpretation. A bioinformatics pipeline to separate donor tumor and mouse stroma transcriptome profiles was devised and tested. To examine the molecular fidelity of PDX versus donor tumors, we compared mRNA differences between paired PDX-donor tumors from nine ovarian cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-42680-2DOI Listing

SMURF1-mediated ubiquitination of ARHGAP26 promotes ovarian cancer cell invasion and migration.

Exp Mol Med 2019 Apr 19;51(4):46. Epub 2019 Apr 19.

Department of Obstetrics and Gynecology, Bao'an Maternity and Child Health Hospital, Jinan University, Shenzhen, 518100, China.

Rho GTPase-activating protein 26 (ARHGAP26) is a negative regulator of the Rho family that converts the small GTP-binding protein RhoA (GTP-RhoA) to its inactive GDP-bound form and is a putative tumor suppressor gene associated with cell growth and migration. Here, the involvement of ARHGAP26 in ovarian cancer cell proliferation and migration was investigated. In this study, low ARHGAP26 expression was observed in ovarian cancer tissues and was associated with a poor overall survival and higher β-catenin expression in patients with ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s12276-019-0236-0
Publisher Site
http://dx.doi.org/10.1038/s12276-019-0236-0DOI Listing
April 2019
1 Read
3.446 Impact Factor

Detection of cell-free, exosomal and whole blood mitochondrial DNA copy number in plasma or whole blood of patients with serous epithelial ovarian cancer.

J Biotechnol 2019 Apr 16. Epub 2019 Apr 16.

Department of Human Genetics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Ovarian tumor is one of the leading causes of cancer among women. Patients are diagnosed at an advanced stage, usually. There is a need for new specific and sensitive biomarkers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbiotec.2019.04.015DOI Listing

A 19‑miRNA Support Vector Machine classifier and a 6‑miRNA risk score system designed for ovarian cancer patients.

Oncol Rep 2019 Apr 10. Epub 2019 Apr 10.

Department of Anesthesiology, Beijing Obstetrics and Gynecology Hospital, Dongcheng, Beijing 100001, P.R. China.

Ovarian cancer (OC) is the most common gynecologic malignancy with high incidence and mortality. The present study aimed to develop approaches for determining the recurrence type and identify potential miRNA markers for OC prognosis. The miRNA expression profile of OC (the training set, including 390 samples with recurrence information) was downloaded from The Cancer Genome Atlas database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2019.7108DOI Listing

SMYD3 promotes epithelial ovarian cancer metastasis by down-regulating p53 protein stability and promoting p53 ubiquitination.

Carcinogenesis 2019 Apr 19. Epub 2019 Apr 19.

Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, China.

Epithelial ovarian cancer (EOC) has a very poor prognosis because of tumor invasiveness. Here, we reported that SMYD3 a lysine methyltransferase was frequently upregulated in EOC and associated with poor prognosis. A series of in vitro assays demonstrated that SMYD3 significantly upgraded the migration ability of EOC cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgz078DOI Listing

Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women.

Cancer Med 2019 Apr 18. Epub 2019 Apr 18.

Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia.

An association between genetic variants in the vitamin D receptor (VDR) gene and epithelial ovarian cancer (EOC) was previously reported in women of African ancestry (AA). We sought to examine associations between genetic variants in VDR and additional genes from vitamin D biosynthesis and pathway targets (EGFR, UGT1A, UGT2A1/2, UGT2B, CYP3A4/5, CYP2R1, CYP27B1, CYP24A1, CYP11A1, and GC). Genotyping was performed using the custom-designed 533,631 SNP Illumina OncoArray with imputation to the 1,000 Genomes Phase 3 v5 reference set in 755 EOC cases, including 537 high-grade serous (HGSOC), and 1,235 controls. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.1996
Publisher Site
http://dx.doi.org/10.1002/cam4.1996DOI Listing
April 2019
1 Read

Analysis of Prophylactic Salpingo-oophorectomy at the Time of Hysterectomy for Benign Lesions.

J Midlife Health 2019 Jan-Mar;10(1):29-32

Department of Obstetrics and Gynecology, NKP Salve Institute of Medical Sciences and Research Centre, Nagpur, Maharashtra, India.

Background: Prophylactic salpingo-oophorectomy refers to the removal of clinically normal ovaries at the time of hysterectomy for benign lesions, to reduce the risk of ovarian and breast cancer in future. This risk reduction holds true for high-risk women, i.e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jmh.JMH_70_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459073PMC

Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway.

Cancer Cell Int 2019 5;19:86. Epub 2019 Apr 5.

1Department of Obstetrics and Gynecology, The Second Hospital of Anhui Medical University, Hefei, 230601 People's Republic of China.

Background: Ovarian cancer is known as one of the most common cancers in the world among women. ST6GALNAC1 is highly expressed in cancer stem cells (CSCs), which correlates to high tumor-initiating, self-renewal and differentiation abilities. This present study aims to investigate how ST6GALNAC1 affects ovarian cancer stem cells (OCSCs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0780-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451308PMC

The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis.

J Ovarian Res 2019 Apr 17;12(1):33. Epub 2019 Apr 17.

Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, No.8, industrial south road, Chaoyang District, Beijing, China.

Background And Objective: Previous studies about the prognostic value of the HIPEC have yielded controversial results. Therefore, this study aims to assess the impact of HIPEC on patients with ovarian cancer.

Results: We included 13 comparative studies, and found that the overall survival (OS) and progression-free survival (PFS) in HIPEC groups were superior to groups without HIPEC treatment in the all total population (HR = 0. Read More

View Article

Download full-text PDF

Source
https://ovarianresearch.biomedcentral.com/articles/10.1186/s
Publisher Site
http://dx.doi.org/10.1186/s13048-019-0509-1DOI Listing
April 2019
1 Read

Endometriosis.

Endocr Rev 2019 Apr 17. Epub 2019 Apr 17.

Departments of Obstetrics and Gynecology, Northwestern University, Chicago, IL.

Pelvic endometriosis is a complex syndrome characterized by an estrogen-dependent chronic inflammatory process that affects primarily pelvic tissues, including the ovaries. It is caused when shed endometrial tissue travels retrograde into the lower abdominal cavity. Endometriosis is the most common cause of chronic pelvic pain in women and is associated with infertility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/er.2018-00242DOI Listing
April 2019
1 Read
21.059 Impact Factor

Genetic counseling referral for ovarian cancer patients: a call to action.

Fam Cancer 2019 Apr 16. Epub 2019 Apr 16.

Thorton Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, VA, USA.

The hereditary contribution to ovarian cancer has been increasingly recognized over the past decade, with a 2014 Society of Gynecologic Oncology (SGO) recommendation for all women with epithelial ovarian cancer to be considered for genetic testing. The objective of the study was to determine if disparities exist in genetic referrals and characterize referral patterns over time. A retrospective cohort study included all women diagnosed with invasive epithelial ovarian cancer at the University of Virginia from 2004 to 2015. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10689-019-00129-5
Publisher Site
http://dx.doi.org/10.1007/s10689-019-00129-5DOI Listing
April 2019
1 Read

Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients.

Int J Gynecol Cancer 2019 Apr 16. Epub 2019 Apr 16.

Obstetrics and Gynecology, Gynecology Oncology Unit. Department of Women's and Children's Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, Rome, Italy.

Objective: There are no current guidelines regarding evaluation of patients with normal CA125 at initial diagnosis during routine surveillance after completion of treatment. Thus, the purpose of this study was to evaluate the role of human epididymis protein 4 (HE4) in the detection of recurrence in patients with ovarian cancer and a negative CA125 at diagnosis.

Methods: All patients with ovarian cancer with a negative CA125 referred to the Division of Gynecologic Oncology of the University Campus Bio-Medico of Rome were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2019-000211DOI Listing

Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?

Gynecol Oncol 2019 Apr 13. Epub 2019 Apr 13.

Center for Biomarkers and Emerging Technologies, Women and Infants Hospital/Brown University, RI 02905, USA; Department of Pathology, Women and Infants Hospital/Brown University, RI 02905, USA.

Introduction: Management of a woman with a pelvic mass is complicated by difficulty in discriminating malignant from benign disease. Many serum biomarkers have been examined to determine their sensitivity for detecting malignancy. This study was designed to evaluate if the addition of biomarkers to HE4 and CA125, as used in the Risk of Malignancy Algorithm (ROMA), can improve the detection of EOC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.006DOI Listing

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

Authors:
Manuel A Ferreira Eric R Gamazon Fares Al-Ejeh Kristiina Aittomäki Irene L Andrulis Hoda Anton-Culver Adalgeir Arason Volker Arndt Kristan J Aronson Banu K Arun Ella Asseryanis Jacopo Azzollini Judith Balmaña Daniel R Barnes Daniel Barrowdale Matthias W Beckmann Sabine Behrens Javier Benitez Marina Bermisheva Katarzyna Białkowska Carl Blomqvist Natalia V Bogdanova Stig E Bojesen Manjeet K Bolla Ake Borg Hiltrud Brauch Hermann Brenner Annegien Broeks Barbara Burwinkel Trinidad Caldés Maria A Caligo Daniele Campa Ian Campbell Federico Canzian Jonathan Carter Brian D Carter Jose E Castelao Jenny Chang-Claude Stephen J Chanock Hans Christiansen Wendy K Chung Kathleen B M Claes Christine L Clarke Fergus J Couch Angela Cox Simon S Cross Kamila Czene Mary B Daly Miguel de la Hoya Joe Dennis Peter Devilee Orland Diez Thilo Dörk Alison M Dunning Miriam Dwek Diana M Eccles Bent Ejlertsen Carolina Ellberg Christoph Engel Mikael Eriksson Peter A Fasching Olivia Fletcher Henrik Flyger Eitan Friedman Debra Frost Marike Gabrielson Manuela Gago-Dominguez Patricia A Ganz Susan M Gapstur Judy Garber Montserrat García-Closas José A García-Sáenz Mia M Gaudet Graham G Giles Gord Glendon Andrew K Godwin Mark S Goldberg David E Goldgar Anna González-Neira Mark H Greene Jacek Gronwald Pascal Guénel Christopher A Haiman Per Hall Ute Hamann Wei He Jane Heyworth Frans B L Hogervorst Antoinette Hollestelle Robert N Hoover John L Hopper Peter J Hulick Keith Humphreys Evgeny N Imyanitov Claudine Isaacs Milena Jakimovska Anna Jakubowska Paul A James Ramunas Janavicius Rachel C Jankowitz Esther M John Nichola Johnson Vijai Joseph Beth Y Karlan Elza Khusnutdinova Johanna I Kiiski Yon-Dschun Ko Michael E Jones Irene Konstantopoulou Vessela N Kristensen Yael Laitman Diether Lambrechts Conxi Lazaro Goska Leslie Jenny Lester Fabienne Lesueur Sara Lindström Jirong Long Jennifer T Loud Jan Lubiński Enes Makalic Arto Mannermaa Mehdi Manoochehri Sara Margolin Tabea Maurer Dimitrios Mavroudis Lesley McGuffog Alfons Meindl Usha Menon Kyriaki Michailidou Austin Miller Marco Montagna Fernando Moreno Lidia Moserle Anna Marie Mulligan Katherine L Nathanson Susan L Neuhausen Heli Nevanlinna Ines Nevelsteen Finn C Nielsen Liene Nikitina-Zake Robert L Nussbaum Kenneth Offit Edith Olah Olufunmilayo I Olopade Håkan Olsson Ana Osorio Janos Papp Tjoung-Won Park-Simon Michael T Parsons Inge Sokilde Pedersen Ana Peixoto Paolo Peterlongo Paul D P Pharoah Dijana Plaseska-Karanfilska Bruce Poppe Nadege Presneau Paolo Radice Johanna Rantala Gad Rennert Harvey A Risch Emmanouil Saloustros Kristin Sanden Elinor J Sawyer Marjanka K Schmidt Rita K Schmutzler Priyanka Sharma Xiao-Ou Shu Jacques Simard Christian F Singer Penny Soucy Melissa C Southey John J Spinelli Amanda B Spurdle Jennifer Stone Anthony J Swerdlow William J Tapper Jack A Taylor Manuel R Teixeira Mary Beth Terry Alex Teulé Mads Thomassen Kathrin Thöne Darcy L Thull Marc Tischkowitz Amanda E Toland Diana Torres Thérèse Truong Nadine Tung Celine M Vachon Christi J van Asperen Ans M W van den Ouweland Elizabeth J van Rensburg Ana Vega Alessandra Viel Qin Wang Barbara Wappenschmidt Jeffrey N Weitzel Camilla Wendt Robert Winqvist Xiaohong R Yang Drakoulis Yannoukakos Argyrios Ziogas Peter Kraft Antonis C Antoniou Wei Zheng Douglas F Easton Roger L Milne Jonathan Beesley Georgia Chenevix-Trench

Nat Commun 2019 Apr 15;10(1):1741. Epub 2019 Apr 15.

Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, 4006, Australia.

Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue and immune cells from blood and spleen. Using expression quantitative trait loci (eQTL) reported in these tissues, we identify 26 previously unreported, likely target genes of overall breast cancer risk variants, and 17 for estrogen receptor (ER)-negative breast cancer, several with a known immune function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-08053-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465407PMC
April 2019
1 Read

ALKBH5 inhibited autophagy of epithelial ovarian cancer through miR-7 and BCL-2.

J Exp Clin Cancer Res 2019 Apr 15;38(1):163. Epub 2019 Apr 15.

Department of Obstetrics and Gynecology, Second Affiliated Hospital, Chongqing Medical University, Linjiang Road, No. 76, Chongqing, 400010, China.

Background: ALKBH5 regulated the malignant behavior of breast cancer and glioblastoma. However, the expression and function of ALKBH5 in epithelial ovarian cancer have not yet been determined. In the present study, we investigated the expression and function of ALKBH5 in epithelial ovarian cancer with respect to its potential role in the tumorigenesis of the disease as well as an early diagnostic marker. Read More

View Article

Download full-text PDF

Source
https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-
Publisher Site
http://dx.doi.org/10.1186/s13046-019-1159-2DOI Listing
April 2019
2 Reads

Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis.

Cancers (Basel) 2019 Apr 2;11(4). Epub 2019 Apr 2.

Graduate Institution of Clinical Medical Science, and Graduate Institute of BioMedical Sciences, School of Medicine, China Medical University, Taichung 40403, Taiwan.

Background: Epithelial ovarian cancer (EOC) is one of the most lethal gynecological malignancies and presents chemoresistance after chemotherapy treatment. Androgen receptor (AR) has been known to participate in proliferation. Yet the mechanisms of the resistance of this drug and its linkage to the AR remains unclear. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/2072-6694/11/4/463
Publisher Site
http://dx.doi.org/10.3390/cancers11040463DOI Listing
April 2019
1 Read

Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases.

Arch Gynecol Obstet 2019 Apr 13. Epub 2019 Apr 13.

Division of Gynecologic Oncology, Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Etlik, 06010, Ankara, Turkey.

Purpose: To investigate the clinico-pathological prognostic factors and treatment outcomes in patients with ovarian yolk sac tumors (YST).

Methods: A multicenter, retrospective department database review was performed to identify patients with ovarian YST who underwent surgery between 2000 and 2017 at seven Gynecologic Oncology Centers in Turkey.

Results: The study group consisted of 99 consecutive patients with a mean age of 23. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00404-019-05160-6
Publisher Site
http://dx.doi.org/10.1007/s00404-019-05160-6DOI Listing
April 2019
2 Reads

Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).

J Med Genet 2019 Apr 12. Epub 2019 Apr 12.

Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte Evangelische Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.

Background: For individuals with ovarian cancer (OC), therapy options mainly depend on germline status. What is the prevalence of deleterious somatic variants, that is, does genetic tumour testing identify subgroups of individuals who also might benefit from targeted therapy?

Methods: Paired analysis of tumour-derived versus blood-derived DNA to determine the prevalence of deleterious somatic variants in OC predisposition genes (, , , , and ) and the and genes in individuals with OC (AGO-TR1 study, NCT02222883). Results were complemented by , and promoter methylation analyses and stratified by histological subtype; 473 individuals were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jmedgenet-2018-105930DOI Listing
April 2019
1 Read

Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.

Clin Cancer Res 2019 Apr 11. Epub 2019 Apr 11.

Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Minato-ku, Tokyo, Japan.

We aimed to develop an ovarian cancer-specific predictive framework for clinical stage, histotype, residual tumor burden, and prognosis using machine learning methods based on multiple biomarkers. Overall, 334 patients with epithelial ovarian cancer (EOC) and 101 patients with benign ovarian tumors were randomly assigned to "training" and "test" cohorts. Seven supervised machine learning classifiers, including Gradient Boosting Machine (GBM), Support Vector Machine, Random Forest (RF), Conditional RF (CRF), Naïve Bayes, Neural Network, and Elastic Net, were used to derive diagnostic and prognostic information from 32 parameters commonly available from pretreatment peripheral blood tests and age. Read More

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-3378DOI Listing
April 2019
2 Reads

Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer.

EBioMedicine 2019 Apr 9. Epub 2019 Apr 9.

Division of Hematology/Oncology, Department of Medicine, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Los Angeles, CA 90095, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523964193024
Publisher Site
http://dx.doi.org/10.1016/j.ebiom.2019.04.009DOI Listing
April 2019
1 Read

ALPL regulates the aggressive potential of high grade serous ovarian cancer cells via a non-canonical WNT pathway.

Biochem Biophys Res Commun 2019 Apr 9. Epub 2019 Apr 9.

Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing, Medical University, Chongqing, 400016, China. Electronic address:

The ALPL gene is linked to hypophosphatasia, a rare genetic disease. Owing to the inverse relationships between ALPL expression and both the International Federation of Gynecology and Obstetrics (FIGO) stages and histological grades assigned to patients with serous ovarian cancer (SOC), this study was designed to explore the role and possible mechanisms of ALPL in cell motility of high grade SOC (HGSOC). The effects of ALPL overexpression on migration and invasion were detected in HGSOC cell lines SKOV3 and HEY. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2019.04.016DOI Listing
April 2019
1 Read

The expression of Platelet-Derived Growth Factor Receptors (PDGFRs) and their correlation with overall survival of patients with ovarian cancer.

Ginekol Pol 2019 Apr 12. Epub 2019 Apr 12.

Department of Neurochemistry and Neuropathology, Poznan University of Medical Sciences, Poznan, Poland.

Objectives: The main aim of the study was to investigate the expression of Platelet-Derived Growth Factor Receptors alpha (PDGFR-alpha) and beta (PDGFR-beta) in malignant and benign ovarian tumors. We performed an analysis of the correlation of PDGFRs expression and stage of the disease, tumor grade and histopathological type of epithelial ovarian cancer (EOC). Additionally, we evaluated patient prognosis according to PDGFR expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/GP.a2019.0045DOI Listing
April 2019
3 Reads

Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.

Cell Death Dis 2019 Apr 11;10(4):322. Epub 2019 Apr 11.

Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

We studied Akt inhibition using SC66 in a NOD-SCID xenograft mouse model and a panel of eight ovarian cancer cell lines. Elevated phospho-Akt levels in cancerous tissue were associated with short progression-free survival and overall survival. Cell sensitivity to SC66 was inversely correlated with phospho-Akt and COL11A1 expression levels, as well as resistance to cisplatin or paclitaxel. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-019-1555-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459878PMC

Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.

Mol Genet Genomic Med 2019 Apr 10:e672. Epub 2019 Apr 10.

Sanway Gene Technology Inc., Changsha, China.

Background: The serum tumor markers has been widely used in ovarian cancer diagnosis. BRCA1/2 germline mutations are the most common predisposing factors for ovarian cancer development. This study aimed to comprehensively investigate serum tumor markers and BRCA1/2 germline mutations and analyze their associations with ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mgg3.672DOI Listing
April 2019
3 Reads

Combined inhibition of FGFR and mTOR pathways is effective in suppressing ovarian cancer.

Am J Transl Res 2019 15;11(3):1616-1625. Epub 2019 Mar 15.

The Third Affiliated Hospital of Jinzhou Medical University Jinzhou 121001, P. R. China.

The PI3K/AKT/mTOR signaling pathway is considered as a promising therapeutic target in the treatment of ovarian cancer (OC); however, inhibition of this pathway only exhibited moderate clinical efficacy when tested clinically. Combination of mTOR inhibitors with other anticancer compounds could improve the anticancer efficiency. Therefore, the concurrent inhibition of Fibroblast Growth Factor Receptor (FGFR) signaling pathway was evaluated in the present study. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456542PMC
March 2019
1 Read

International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.

Br J Cancer 2019 Apr 11. Epub 2019 Apr 11.

Women's College Research Institute, Toronto, ON, Canada.

Background: Women with a BRCA1 or BRCA2 mutation face high risks of breast and ovarian cancer. In the current study, we report on uptake of cancer screening and risk-reduction options in a cohort of BRCA mutation carriers from ten countries over two time periods (1995 to 2008 and 2009 to 2017).

Methods: Eligible subjects were identified from an international database of female BRCA mutation carriers and included women from 59 centres from ten countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0446-1DOI Listing

Outcomes of non-high grade serous carcinoma after neoadjuvant chemotherapy for advanced-stage ovarian cancer: a Korean gynecologic oncology group study (OV 1708).

BMC Cancer 2019 Apr 11;19(1):341. Epub 2019 Apr 11.

Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Dankook University College of Medicine, Seoul, South Korea.

Background: Outcomes of patients with ovarian high-grade serous carcinoma (HGSC) treated with neoadjuvant chemotherapy (NAC) have been widely studied, but there is limited information on the outcomes of patients with non-HGSC. This study aimed to evaluate the outcomes of NAC in non-HGSC patients with advanced-stage ovarian cancer.

Methods: We conducted a retrospective cohort study of patients who underwent NAC for advanced stage non-HGSC between 2002 and 2017 in 17 institutions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5514-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458623PMC
April 2019
1 Read

Mining Featured Biomarkers Linked with Epithelial Ovarian CancerBased on Bioinformatics.

Diagnostics (Basel) 2019 Apr 9;9(2). Epub 2019 Apr 9.

Biostatistics and Bioinformatics,Chanabasava Nilaya, Bharthinagar,Dharwad, Karanataka 580001, India.

Epithelial ovarian cancer (EOC) is the18th most common cancer worldwide and the 8th most common in women. The aim of this study was to diagnose the potential importance of, as well as novel genes linked with, EOC and to provide valid biological information for further research. The gene expression profiles of E-MTAB-3706 which contained four high-grade ovarian epithelial cancer samples, four normal fallopian tube samples and four normal ovarian epithelium samples were downloaded from the ArrayExpress database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/diagnostics9020039DOI Listing
April 2019
3 Reads

Prognostic value of tissue plasminogen activator (tPA) in patients with epithelial ovarian cancer undergoing chemotherapy.

Ginekol Pol 2019 Apr 10. Epub 2019 Apr 10.

2nd Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland.

Objectives: Tissue plasminogen activator (tPA) is a key enzyme for fibrin degradation and the proteolytic defense against formation of the thrombotic endothelial deposits. tPA is involved in carcinogenesis but its exact role in tumor biology is not very well understood and a prognostic value of tPA remains ambiguous in different cancers. The aim of the study was to assess the prognostic value of plasma tPA in patients with epithelial ovarian cancer (EOC) in the course of the first line chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/GP.a2019.0043DOI Listing
April 2019
1 Read

Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma is Not Associated with Pathological Misclassification of Tumor Histotype.

Clin Cancer Res 2019 Apr 9. Epub 2019 Apr 9.

Cancer Genetics and Genomics Laboratory and Austrialian Ovarian Cancer Study, Peter MacCallum Cancer Centre

Purpose: Although ovarian clear cell carcinomas (OCCCs) are commonly resistant to platinum based chemotherapy, good clinical outcomes are observed in a subset of patients. The explanation for this is unknown but may be due to misclassification of high-grade serous ovarian cancer (HGSOC) as OCCC or mixed histology.

Experimental Design: To discover potential biomarkers of survival benefit following platinum based chemotherapy, we ascertained a cohort of 68 Japanese and Australian patients in whom progression-free survival (PFS) and overall survival (OS) could be assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3691DOI Listing
April 2019
1 Read

CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer.

Tumour Biol 2019 Apr;42(4):1010428319842699

1 Department of Obstetrics and Gynecology, Guro Hospital, College of Medicine, Korea University, Seoul, Republic of Korea.

Objectives: Adiponectin is a cytokine secreted from adipose tissue that regulates energy homeostasis, inflammation, and cell proliferation. Obesity is associated with increased risk of various cancers, including ovarian cancer. Adipokines, including adiponectin, have been implicated as a factor linking obesity and carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1010428319842699DOI Listing
April 2019
1 Read

A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer.

Cancers (Basel) 2019 Apr 8;11(4). Epub 2019 Apr 8.

Department of Obstetrics and Gynecology, Northwestern University, Chicago, IL 60611, USA.

A small of population of slow cycling and chemo-resistant cells referred to as cancer stem cells (CSC) have been implicated in cancer recurrence. There is emerging interest in developing targeted therapeutics to eradicate CSCs. Aldehyde-dehydrogenase (ALDH) activity was shown to be a functional marker of CSCs in ovarian cancer (OC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11040502DOI Listing
April 2019
1 Read

circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge.

Biomed Pharmacother 2019 Apr 4;114:108832. Epub 2019 Apr 4.

Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Key Laboratory for Major Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institute in Guangdong Province, Guangzhou, 510150, China. Electronic address:

Circular RNAs are known to participate in tumorigenesis through a variety of pathways, and as such, have potential to serve as molecular markers in tumor diagnosis and treatment. Here, using quantitative reverse transcription (qRT)-PCR, we showed that circ-CSPP1 is highly expressed in ovarian cancer (OC) tissues. Particularly, we detected circ-CSPP1 expression in three OC cell lines; of which, OVCAR3 and A2780 demonstrated higher levels of circ-CSPP1 expression, and CAOV3 showed lower circ-CSPP1 expression level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2019.108832DOI Listing
April 2019
3 Reads
2.023 Impact Factor

Ovarian mucinous carcinoma with mural carcinosarcomatous components in a prepubertal girl.

J Pediatr Adolesc Gynecol 2019 Apr 6. Epub 2019 Apr 6.

Department of Obstetrics and Gynecology, Dokkyo Medical University Saitama Medical Center, Koshigaya Japan.

Background: Epithelial ovarian cancer development before menarche is extremely rare.

Case: We report a prepubertal girl who developed ovarian mucinous carcinoma with mural carcinosarcomatous components.

Summary And Conclusion: Magnetic resonance imaging showed a polycystic mass with solid components. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpag.2019.04.005DOI Listing
April 2019
1 Read
1.812 Impact Factor

The expression and significance of lncRNA HOST2 and microRNA let-7b in HPV-positive cervical cancer tissues and cell lines.

Eur Rev Med Pharmacol Sci 2019 Mar;23(6):2380-2390

Department of Obstetrics and Gynecology, Hebei Medical University, Shijiazhuang, Hebei, China.

Objective: This study attempted to investigate the expression and significance of lncRNA HOST2 (human ovarian cancer-specific transcript 2) and microRNA let-7b in human papillomavirus (HPV)-positive cervical cancer (CC) tissues and cell lines.

Patients And Methods: The expression of levels of HOST2 and let-7b were detected by qRT-PCR in HPV-positive CC tissues and cell lines. The HPV-positive CaSki and HeLa cells were divided into the Blank, NC, pcDNA3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_201903_17384DOI Listing
March 2019
1 Read

MiR-539-3p promotes the progression of epithelial ovarian cancer by targeting SPARCL1.

Authors:
Y-B Gong X-H Fan

Eur Rev Med Pharmacol Sci 2019 Mar;23(6):2366-2373

Department of Obstetrics and Gynecology, Hanchuan People's Hospital, Hanchuan, China.

Objective: The aim of this study was to investigate the effect of microRNA-539-3p (miR-539-3p) on the development of epithelial ovarian cancer (EOC), and to explore the possible underlying mechanism.

Patients And Methods: A total of 40 paired EOC tissues and adjacent normal ovarian tissues were surgically resected in Hanchuan People's Hospital. Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) was used to detect the expression of miR-539-3p in EOC tissues and cell lines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_201903_17381DOI Listing
March 2019
1 Read

Long noncoding RNA DARS-AS1 acts as an oncogene by targeting miR-532-3p in ovarian cancer.

Eur Rev Med Pharmacol Sci 2019 Mar;23(6):2353-2359

Department of Obstetrics and Gynecology, Hanchuan People's Hospital, Hanchuan, China.

Objective: Ovarian cancer is one of the most ordinary malignant tumors. Recently, the role of long noncoding RNAs (lncRNAs) in tumor progression has caught attention of numerous researchers. In this research, lncRNA DARS-AS1 was studied to identify how it functions in the development of ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://www.europeanreview.org/article/17379
Publisher Site
http://dx.doi.org/10.26355/eurrev_201903_17379DOI Listing
March 2019
10 Reads

LncRNA SNHG12 accelerates the progression of ovarian cancer via absorbing miRNA-129 to upregulate SOX4.

Authors:
D Sun X-H Fan

Eur Rev Med Pharmacol Sci 2019 Mar;23(6):2345-2352

Department of Obstetrics and Gynecology, Hanchuan People's Hospital, Hanchuan, China.

Objective: To clarify whether long non-coding RNA (lncRNA) SNHG12 could regulate the proliferative and migratory abilities of ovarian cancer (OC) cells through mediating microRNA-129 (miRNA-129), thus influencing the progression of OC.

Patients And Methods: The expression patterns of SNHG12 and miRNA-129 in OC tissues and adjacent normal tissues were determined by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Meanwhile, their expression levels in OC cell lines were also examined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26355/eurrev_201903_17378DOI Listing
March 2019
1 Read

Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study.

Eur Radiol 2019 Apr 8. Epub 2019 Apr 8.

Department of Radiology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, People's Republic of China.

Purpose: To evaluate the ability of MRI radiomics to categorize ovarian masses and to determine the association between MRI radiomics and survival among ovarian epithelial cancer (OEC) patients.

Method: A total of 286 patients with pathologically proven adnexal tumor were retrospectively included in this study. We evaluated diagnostic performance of the signatures derived from MRI radiomics in differentiating (1) between benign adnexal tumors and malignancies and (2) between type I and type II OEC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-019-06124-9DOI Listing
April 2019
1 Read

Laparoscopic diverting loop ileostomy for spontaneous colon perforation in advanced ovarian cancer.

Authors:
John O Schorge

Gynecol Oncol Rep 2019 May 20;28:84-85. Epub 2019 Mar 20.

Department of Obstetrics and Gynecology, Tufts Medical Center, Boston, MA 02111, United States of America.

Objective: Neoadjuvant chemotherapy for advanced ovarian cancer is associated with reduced morbidity in the elderly (Meyer et al., 2018). Spontaneous colonic perforation often leads to multisystem organ failure and death (Carter and Durfee, 2007; Rose and Piver, 1995). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gore.2019.03.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434062PMC
May 2019
1 Read

infection in primary fallopian tube and high-grade serous ovarian cancers: a pilot study.

Int J Womens Health 2019 22;11:199-205. Epub 2019 Mar 22.

Family Medicine Department, Royal Australian College of General Practitioners, Sydney, Australia.

Background: The aim of this study was to evaluate the association of (CT) infection with primary tubal and high-grade serous ovarian cancers.

Methods: This is a cross-sectional, retrospective study conducted at Ain Shams University Maternity Hospital, Egypt, from February 2008 to October 2017. Sixty-seven paraffin archival blocks specimens were retrieved from cases who underwent staging laparotomy due to high-grade serous ovarian cancer (30 cases), primary tubal serous cancer (25 cases), and control specimens of (12) tubal specimens from cases of benign gynecological conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJWH.S188938DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434919PMC
March 2019
2 Reads

Exosomal transfer of miR-124 inhibits normal fibroblasts to cancer-associated fibroblasts transition by targeting sphingosine kinase 1 in ovarian cancer.

J Cell Biochem 2019 Apr 7. Epub 2019 Apr 7.

Department of Obstetrics and Gynecology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

Objective: The interaction between tumor microenvironment and tumor cells plays a key role in tumor progression. However, the mechanisms by which this interaction promotes the transdifferentiation of normal fibroblasts (NFs) to cancer-associated fibroblasts (CAFs) are still unclear. The aim of this study was to investigate whether ovarian cancer (OvCa) cells-derived microRNAs were involved in the transition of resident fibroblasts to CAFs, and in promoting tumorigenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.28593DOI Listing
April 2019
2 Reads

Circulating epithelial-mesenchymal transition-associated miRNAs are promising biomarkers in ovarian cancer.

J Biotechnol 2019 May 3;297:58-65. Epub 2019 Apr 3.

Department of Human Genetics, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Electronic address:

Ovarian cancer is the fifth most common cause of cancer death among women that is mostly due to the difficulty of early diagnosis. Circulating miRNAs proved to be reliable biomarkers in various cancers. We screened 9 miRNAs, which are involved in epithelial-mesenchymal transition, in the plasma samples of patients with malignant (n = 28) or non-malignant (n = 12) ovarian tumors and disease-free healthy volunteers (n = 60) by qRT-PCR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbiotec.2019.04.003DOI Listing

Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort.

Breast J 2019 Apr 5. Epub 2019 Apr 5.

Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.

The detection of deleterious germline mutations in BRCA1 and BRCA2 considerably influences the clinical management of healthy and diseased carriers. Therefore, the identification of persons at risk who could uptake genetic counseling and testing is pivotal. We developed a checklist with validated criteria to improve the identification, and prospectively evaluate the incidence, of familial cancer history in 5091 breast cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/tbj.13257DOI Listing
April 2019
2 Reads

Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.

Gynecol Oncol 2019 Apr 2. Epub 2019 Apr 2.

Department of Gynecologic Oncology Department, University Hospital La Fe, Valencia, Spain.

Objective: To determine pre-/intraoperative risk factors for anastomotic leak after modified posterior pelvic exenteration (MPE) or colorectal resection in ovarian cancer and to create a practical instrument for predicting anastomotic leak risk.

Background: In advanced ovarian cancer surgery, there is rather limited published evidence, drawn from a small sample, providing information about risk factors for anastomotic leak.

Methods: Eight hospitals participated in this retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.241DOI Listing
April 2019
2 Reads

Ovarian serous carcinoma in synthetic mesh: A rare case report and review of the literature.

J Obstet Gynaecol Res 2019 Apr 5. Epub 2019 Apr 5.

Department of Obstetrics and Gynecology, Barzilai Medical Center, Ben Gurion University of the Negev, Ashkelon, Israel.

Epithelial ovarian cancer relapse is a devastating condition with a poor prognosis. Synthetic mesh carcinogenicity is an entity scarcely reported in the literature. We present a rare case of an ovarian serous tumor relapsed in a polypropylene mesh previously inserted for pelvic organ prolapse correction and a review of the available literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jog.13963DOI Listing
April 2019
3 Reads

Tubal Origin of "Ovarian" Low-Grade Serous Carcinoma: A Gene Expression Profile Study.

J Oncol 2019 5;2019:8659754. Epub 2019 Mar 5.

Department of Obstetrics and Gynecology, Henan Provincial People's Hospital, Zhengzhou, China.

Objective: Ovarian low-grade serous carcinomas are thought to evolve in a stepwise fashion from ovarian epithelial inclusions, serous cystadenomas, and serous borderline tumors. Our previous study with clinicopathological approach showed that the majority ovarian epithelial inclusions are derived from the fallopian tubal epithelia rather than from ovarian surface epithelia. This study was designed to gain further insight into the cellular origin of ovarian low-grade serous carcinomas by differential gene expression profiling studies. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/jo/2019/8659754/
Publisher Site
http://dx.doi.org/10.1155/2019/8659754DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425354PMC
March 2019
11 Reads

Predicting circulating CA125 levels among healthy premenopausal women.

Cancer Epidemiol Biomarkers Prev 2019 Apr 4. Epub 2019 Apr 4.

Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School.

Background: CA125 is the most promising ovarian cancer screening biomarker to date. Multiple studies reported CA125 levels vary by personal characteristics, which could inform personalized CA125 thresholds. However, this has not been well described in premenopausal women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-18-1120DOI Listing
April 2019
3 Reads

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Lancet Oncol 2019 Apr 1. Epub 2019 Apr 1.

Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St Joseph's Hospital, Phoenix, AZ, USA.

Background: Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5-9 months. In this study (QUADRA), we investigated the activity of niraparib monotherapy as the fourth or later line of therapy.

Methods: QUADRA was a multicentre, open-label, single-arm, phase 2 study that evaluated the safety and activity of niraparib in adult patients (≥18 years) with relapsed, high-grade serous (grade 2 or 3) epithelial ovarian, fallopian tube, or primary peritoneal cancer who had been treated with three or more previous chemotherapy regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30029-4DOI Listing
April 2019
4 Reads